What Is The Mechanism Of Action Of Masitinib
AB1010 powder(masitinib) is a selective tyrosine kinase inhibitor, mainly used to treat specific types of cytopathic and inflammatory diseases. It interferes with the proliferation and growth of diseased cells by inhibiting multiple tyrosine kinases, including KIT, PDGFR, and CSF1R, and plays a role in certain inflammatory and immune-related diseases. It was initially designed to treat cytopathic diseases, especially those associated with abnormal activity of tyrosine kinases, by competitively inhibiting the activity of these enzymes and blocking signal transduction pathways, thereby inhibiting the growth and spread of diseased cells. Currently, masitinib is in multiple clinical trial stages, with the main focus areas including the treatment of cytopathic diseases such as gastrointestinal stromal tumors (GIST) and pancreatic cytopathic diseases; neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease; and inflammatory diseases such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Side effects are similar to other tyrosine kinase inhibitors, and common ones include gastrointestinal reactions, abnormal liver function, skin reactions, and hematological toxicity. Although side effects are common, most patients can tolerate them and can be controlled with dose adjustments. During use, patients' liver function and blood routine tests must be monitored regularly to detect and manage potential side effects promptly. It shows broad therapeutic potential as a multi-target tyrosine kinase inhibitor, but its development path has not been smooth. Key challenges include ensuring its safety and efficacy and its flexible application in different indications. Nevertheless, its multiple mechanisms of action make it an important candidate for future drug development. With further research and clinical trials, masitinib is expected to become one of the essential options for the treatment of cytopathic diseases and inflammatory diseases. Still, attention should be paid to its possible side effects, and strict medical monitoring should be carried out.
What Are The Results Of Masitinib
In treating cytopathic diseases, masitinib has shown the potential to prolong progression-free survival in patients with gastrointestinal stromal tumors (GIST) resistant to imatinib. In addition, preliminary results of patients with advanced or metastatic pancreatic cytopathic diseases have shown that it may improve survival when used in combination with chemotherapy drugs, but further verification is needed. In the field of neurodegenerative diseases, the use of it in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease has shown encouraging results. Clinical trials have demonstrated that it may slow the disease progression of ALS by inhibiting inflammatory pathways and improving patients' functional status and quality of life; in Alzheimer's disease, preliminary data show that it may delay the decline of cognitive function, but more research is needed to confirm. Inflammatory diseases such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE) mainly work through its anti-inflammatory and immunomodulatory effects. Preliminary results show that it may reduce the relapse rate of MS and delay disease progression. At the same time, studies in SLE aim to relieve inflammation and immune responses by inhibiting related tyrosine kinases, and clinical trials are underway. However, masitinib is also accompanied by some side effects, mainly including gastrointestinal reactions such as nausea, vomiting, and diarrhea, abnormal liver function such as elevated liver enzymes, skin reactions such as rash and itching, and hematological toxicity such as leukopenia and thrombocytopenia. In addition, fatigue and loss of appetite are also common side effects. Most patients can tolerate these side effects, which are effectively managed through dose adjustment and symptomatic treatment. However, since it is still in the clinical trial stage for multiple indications, its long-term safety and comprehensive side effect spectrum still need further research and confirmation. Overall, masitinib has shown promising therapeutic effects in areas such as cytopathic diseases and neurodegenerative diseases. However, its efficacy and safety still need to be supported by more clinical trial data. It has not been widely approved for routine clinical treatment, and its future application prospects will depend on the results of ongoing research and the approval progress of regulatory agencies.
What Are The Side Effects Of Masitinib
The dose of masitinib varies depending on the specific indication and the individual patient's condition. Gastrointestinal stromal tumor (GIST): The usual starting dose is 7.5 mg/kg/day, taken orally in two divided doses. If the patient can tolerate it, the dose may gradually increase to a higher level, but the specific adjustment depends on the patient's tolerance and treatment response. Advanced or metastatic pancreatic cell disease: In some studies, masitinib is combined with chemotherapy drugs, and the dose is usually set at 9 mg/kg/day, taken orally in two divided doses. Amyotrophic lateral sclerosis (ALS): The standard dose in clinical trials is 4.5 mg/kg/day, taken orally in two divided doses. The dose may be adjusted based on the patient's response and side effects. Alzheimer's disease: In some studies, it is 4.5 mg/kg/day, taken orally in two divided doses. It should be noted that the dose adjustment of masitinib should be carried out cautiously and under the guidance of professional medical staff. Because its side effects may include gastrointestinal reactions, abnormal liver function, skin reactions, and hematological toxicity, patients need to be monitored regularly during medication to detect and deal with adverse reactions promptly. The doctor should formulate a specific treatment plan based on the patient's specific situation, and any medication use and dosage adjustment should be carried out under professional medical guidance.
At the same time, it is essential to choose products that are of reliable quality. Xi'an Sonwu Biotech Co. Ltd. has rich experience in the global trade and the health industry. Insisting on faith-based and quality first is our company's principle. We strictly control product quality, which means selection starts from raw material. Besides, we handle every detail and reduce costs to the maximum so our customers can get cost-effective products. Based on these, customers have given a lot of good feedback about our products.
If you want to buy masitinib, feel free to contact Xi'an Sonwu.
E-mail: sales@sonwu.com